Skip to main content
Home
  • ALL Specialities ALL Specialities
    Home
    Home

    Ted Bosworth

    News

    Multi-Refractory MM: After Immunotherapy, What?

    Author:
    Ted Bosworth
    Publish date: October 25, 2024

    Experts outlined viable remaining options for treating multi-refractory myeloma, following immunotherapy.

    • Read More

    News

    Lymphoma Debate: CAR T Not a Clear Winner

    Author:
    Ted Bosworth
    Publish date: October 25, 2024

    Fiercely debating on best strategies for treating advanced lymphoma, specialists could not reach consensus.

    • Read More

    News

    Expert Updates Therapy for Waldenström Macroglobulinemia

    Author:
    Ted Bosworth
    Publish date: October 25, 2024

    A specialist applies a novel, nuanced approach to Waldenström macroglobulinemia, based on mutational status.

    • Read More

    News

    Phase 2 Data on New Drug Class for Prurigo Nodularis Promising

    Author:
    Ted Bosworth
    Publish date: October 18, 2024

    At 16 weeks, all povorcitinib doses were superior to placebo in achieving at least a 4-point reduction on the Itch Numerical Rating Scale and the...

    • Read More

    News

    Over 3 Years, Atopic Dermatitis Well-Controlled with Lebrikizumab

    Author:
    Ted Bosworth
    Publish date: October 18, 2024

    “Over the whole follow-up, 90% had no need for topical corticosteroids or any other rescue therapy,” reported Diamant Thaçi, MD, PhD.

    • Read More

    News

    Topical JAK Inhibitor Shows Benefits in Small Frontal Fibrosing Alopecia Study

    Author:
    Ted Bosworth
    Publish date: October 18, 2024

    The slow progress to identify treatments for FFA is illustrated by the fact that only one other double-blind and randomized trial has ever been...

    • Read More

    News

    Different Biomarker Profiles Identified in Study of Late Dupilumab Responders

    Author:
    Ted Bosworth
    Publish date: October 18, 2024

    A discovery that could lead to personalizing therapies, the data identified “distinct systemic biomarker profiles,” Ester Del Duca, MD, said.

    • Read More

    News

    Hidradenitis Suppurativa: Nodules Respond to As Needed Topical JAK Inhibitor

    Author:
    Ted Bosworth
    Publish date: October 18, 2024

    Entry criteria for the study included Hurley stage I or II HS with no draining tunnels. Hurley stage III patients were not eligible.

    • Read More

    News

    sNFl and sGFAP Predict MS Disability in Unique Ways

    Author:
    Ted Bosworth
    Publish date: October 3, 2024

    GFAP might soon join serum neurofilament light chain (sNFl) levels for predicting disability, but each has unique features and they appear to...

    • Read More

    News

    Childhood-Onset Atopic Dermatitis Adds Burden in Adulthood

    Author:
    Ted Bosworth
    Publish date: September 27, 2024

    The Scars of Life project was designed to analyze how the age of AD onset affects the severity of symptoms and quality of life.

    • Read More

    News

    Genetic Testing for ALS, Now a Standard, Creates a Path Toward Individualized Care

    Author:
    Ted Bosworth
    Publish date: September 25, 2024

    Overall, there is a sense of progress in ALS. The hope is that clinical research is reaching a tipping point where targeted treatments may offer...

    • Read More

    News

    Ofatumumab MS Study Supports Early Start Over Switch

    Author:
    Ted Bosworth
    Publish date: September 25, 2024

    New extension data from phase 3 ofatumumab RRMS study, show lower long-term disability accumulation with early-start of the more potent therapy...

    • Read More

    News

    No Signal of Benefit for Simvastatin in Progressive MS

    Author:
    Ted Bosworth
    Publish date: September 23, 2024

    Despite theoretical benefits and an encouraging phase 2 study, a definitive phase 3 trial failed to associate...

    • Read More

    News

    Disability Reduction Is a Twist in Negative BTKi RRMS Trial

    Author:
    Ted Bosworth
    Publish date: September 23, 2024

    In phase 3 RRMS trials, tolebrutinib showed no advantage over teriflunomide for a relapse endpoint, but a disability endpoint advantage might...

    • Read More

    News

    Seborrheic Dermatitis in Black Patients: New Therapies Offer Hope

    Author:
    Ted Bosworth
    Publish date: September 23, 2024

    In patients with darker skin, the signs of seborrheic dermatitis can differ.

    • Read More

    Pages

    • 1
    • 2
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • …
    • last »

    Privacy Policy

    Terms of Use

    Editorial Policy

    Cookie Policy

    Ad Policy

    Medscape Customer Support

    Frequently Asked Questions

     

    Advertise with MDedge

    See more with MDedge! See our Other Publications

    MDedge: Keeping You Informed. Saving You Time.

    Copyright  © 2024 Frontline Medical Communications Inc., 283-299 Market Street, 2 Gateway Center, 4th Floor, Newark, NJ 07102. All rights reserved. Unauthorized use prohibited. The information provided is for educational purposes only. Use of this Web site is subject to the medical disclaimer.

    • All Specialties
      • MDedge Home
      • Cardiology
      • Clinician Reviews
      • Dermatology
      • Emergency Medicine
      • Endocrinology/Diabetes
      • Family Medicine
      • Federal Practitioner
      • Gastroenterology
      • Hematology/Oncology
      • Infectious Disease
      • Internal Medicine
      • Neurology
      • Obstetrics And Gynecology
      • Pediatrics
      • Psychiatry
      • Pulmonology
      • Rheumatology
      • Surgery
    • MDedge Home
    • Cardiology
    • Clinician Reviews
    • Dermatology
    • Emergency Medicine
    • Endocrinology/Diabetes
    • Family Medicine
    • Federal Practitioner
    • Gastroenterology
    • Hematology/Oncology
    • Infectious Disease
    • Internal Medicine
    • Neurology
    • Obstetrics And Gynecology
    • Pediatrics
    • Psychiatry
    • Pulmonology
    • Rheumatology
    • Surgery